Advanced Implantable Cardioverter-Defibrillator

A new implantable cardioverter-defibrillator (ICD) has a longevity rating of seven to eight years and faster charge times that are designed to increase patient safety. The device, called the Marquis DR, has been cleared by the US Food and Drug Administration (FDA) and has received the CE Mark.

The device also features a Cardiac Compass to monitor cardiac disease progression, faster telemetry, and a new leadless electrocardiogram (ECG) function. The Marquis DR's improved longevity is due to a modified battery design that resulted in longer battery life and the need for less-frequent replacement. The device has a charge time of only 7.5 seconds after an eight-year service life, which makes it comparable or better than existing ICDs at implant, says the developer, Medtronic, Inc. (Minneapolis, MN, USA). The Marquis DR is remote-ready and compatible with Medtronic's CareLink Network, which allows patients to remotely download information to a secure server.

"With Marquis DR, we continue to extend and enhance our industry-leading ICD product line with truly significant improvements for our physican customers and their patients,” said Steve Mahle, president of cardiac rhythm management at Medtronic.




Related Links:
Medtronic